These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20337728)

  • 1. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
    Hayashi T; Crain B; Corr M; Chan M; Cottam HB; Maj R; Barberis A; Leoni L; Carson DA
    Int J Urol; 2010 May; 17(5):483-90. PubMed ID: 20337728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial comment from Dr Arum to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
    Arum CJ
    Int J Urol; 2010 May; 17(5):490. PubMed ID: 20415708
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial comment from Dr Olbert to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
    Olbert PJ
    Int J Urol; 2010 May; 17(5):491. PubMed ID: 20415709
    [No Abstract]   [Full Text] [Related]  

  • 4. A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
    Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
    World J Urol; 2018 Nov; 36(11):1719-1725. PubMed ID: 29767328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model.
    Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
    Urol Oncol; 2018 May; 36(5):242.e1-242.e7. PubMed ID: 29500135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs.
    Arentsen HC; Hulsbergen-Van de Kaa CA; Jansen CF; Maj R; Leoni LM; Oosterwijk E; Witjes JA
    BJU Int; 2011 Oct; 108(7):1210-4. PubMed ID: 21314886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
    Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques.
    De Meyer I; Martinet W; Schrijvers DM; Timmermans JP; Bult H; De Meyer GR
    Basic Res Cardiol; 2012 May; 107(3):269. PubMed ID: 22543675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
    Smith EB; Schwartz M; Kawamoto H; You X; Hwang D; Liu H; Scherr DS
    J Urol; 2007 Jun; 177(6):2347-51. PubMed ID: 17509356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
    Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
    Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.
    Donin NM; Chamie K; Lenis AT; Pantuck AJ; Reddy M; Kivlin D; Holldack J; Pozzi R; Hakim G; Karsh LI; Lamm DL; Belkoff LH; Belldegrun AS; Holden S; Shore N
    Urol Oncol; 2017 Feb; 35(2):39.e1-39.e7. PubMed ID: 28341495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor inhibitory effects of intravesical Ganoderma lucidum instillation in the syngeneic orthotopic MB49/C57 bladder cancer mice model.
    Yuen JWM; Mak DSY; Chan ES; Gohel MDI; Ng CF
    J Ethnopharmacol; 2018 Sep; 223():113-121. PubMed ID: 29783018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.
    Furuya H; Chan OTM; Pagano I; Zhu C; Kim N; Peres R; Hokutan K; Alter S; Rhode P; Rosser CJ
    J Transl Med; 2019 Jan; 17(1):29. PubMed ID: 30654801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer.
    Smith SG; Koppolu BP; Ravindranathan S; Kurtz SL; Yang L; Katz MD; Zaharoff DA
    Cancer Immunol Immunother; 2015 Jun; 64(6):689-96. PubMed ID: 25754122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
    Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
    J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.